We report the analysis of PD-L1 expression in matched tumor samples from patients with stage III NSCLC who underwent neoadjuvant CT, CRT, or CT + ICI in the four SAKK trials 16/96, 16/00, 16/01, and 16/14. The gene discussed is CD274; the disease is neoplasm.